Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Department of Orthopedic Surgery, First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, China.
Biopreserv Biobank. 2022 Aug;20(4):401-408. doi: 10.1089/bio.2021.0083. Epub 2021 Oct 12.
High concentrations of cryoprotective agents (CPAs) are required to achieve successful vitrification of articular cartilage; however, CPA cytotoxicity causes chondrocyte death. To reduce CPA toxicity, supplementation with research-grade additives, in particular chondroitin sulfate (CS) and ascorbic acid (AA), have previously been shown to improve chondrocyte recovery and metabolic function after exposure to CPAs at hypothermic conditions. However, it is necessary to evaluate the pharmaceutical equivalent clinical grade of these additives to facilitate the supplementation of additives into future vitrification protocols, which will be designed for vitrifying human articular cartilage in tissue banks. We sought to investigate the effectiveness of clinical-grade CS, AA, and -acetylcysteine (NAC) in mitigating toxicity to chondrocytes during CPA exposure and removal, and determine whether a combination of two additives would further improve chondrocyte viability. We hypothesized that clinical-grade additives would exert chondroprotective effects comparable to those of research-grade additives, and that this protective effect would be enhanced if two additives were combined when compared with a single additive. The results indicated that both clinical-grade and research-grade additives significantly improved cell viability ( < 0.10) compared with the negative control (CPA with no additives). CS, AA, and NAC+AA increased cell viability significantly ( < 0.10) compared with the negative control. However, NAC, NAC+CS, and CS+AA did not improve cell viability when compared with the negative control ( > 0.10). We demonstrated that supplementation with clinical-grade CS or AA significantly improved chondrocyte viability in porcine cartilage subjected to high CPA concentrations, whereas supplementation with clinical-grade NAC did not benefit chondrocyte viability. Supplementation with clinical-grade additives in CPA solutions can mitigate CPA toxicity, which will be important in translating previously developed effective protocols for the vitrification of articular cartilage to human tissue banks.
高浓度的冷冻保护剂 (CPAs) 是实现关节软骨成功玻璃化的必要条件;然而,CPA 的细胞毒性会导致软骨细胞死亡。为了降低 CPA 的毒性,以前已经证明,在低温条件下暴露于 CPA 时,补充研究级添加剂,特别是硫酸软骨素 (CS) 和抗坏血酸 (AA),可以改善软骨细胞的恢复和代谢功能。然而,有必要评估这些添加剂的等效临床级药物,以促进将添加剂添加到未来的玻璃化方案中,这些方案将设计用于在组织库中玻璃化人类关节软骨。我们试图研究临床级 CS、AA 和 N-乙酰半胱氨酸 (NAC) 在减轻 CPA 暴露和去除过程中对软骨细胞毒性的有效性,并确定两种添加剂的组合是否会进一步提高软骨细胞活力。我们假设临床级添加剂会产生与研究级添加剂相当的软骨保护作用,如果与单一添加剂相比,两种添加剂的组合会增强这种保护作用。结果表明,与阴性对照组(无添加剂的 CPA)相比,临床级和研究级添加剂均显著提高了细胞活力( < 0.10)。CS、AA 和 NAC+AA 与阴性对照组相比,显著提高了细胞活力( < 0.10)。然而,与阴性对照组相比,NAC、NAC+CS 和 CS+AA 并未提高细胞活力( > 0.10)。我们证明,在高 CPA 浓度下,猪软骨补充临床级 CS 或 AA 可显著提高软骨细胞活力,而补充临床级 NAC 则不能提高软骨细胞活力。在 CPA 溶液中补充临床级添加剂可以减轻 CPA 的毒性,这对于将以前开发的有效的关节软骨玻璃化方案转化为人类组织库非常重要。